Institute Fires Off Suit Against Amgen Over Royalties

Law360, New York (December 19, 2007, 12:00 AM EST) -- A cancer research center has launched a suit against biotech giant Amgen Inc. for allegedly skimping on more than $72 million in royalty payments on two drugs for preventing infections.

The Sloan-Kettering Institute for Cancer Research filed its action on Wednesday in the U.S. District Court for the Southern District of New York, accusing Amgen of making improper deductions from the sales of Neupogen and Neulasta rebates that are based on the purchase of anemia medication Aranesp.

The miscalculation by the Thousand Oaks, Calif.-based drug maker...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.